Shire PLC

Most Recent

  • uploads///Xyrem
    Company & Industry Overviews

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Recommendations for Shire as of October 30

    Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Shire: Why Analysts Expect Revenue Growth in Q3 2018

    Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.

    By Mike Benson
  • uploads///analysis _
    Earnings Report

    What to Expect from Thermo Fisher’s Third-Quarter Earnings

    Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    A Look at Shire’s Valuation on September 19

    Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.

    By Mike Benson
  • uploads///lab _
    Earnings Report

    How Did Jazz Pharmaceuticals Perform in the Second Quarter?

    Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

    By Daniel Collins
  • uploads///thermometer _
    Earnings Report

    Shire’s Q2 2018 Earnings Beat Analyst Estimates

    Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Shire’s Q2 2018 Earnings on July 31

    Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.

    By Mike Benson
  • uploads///eye blue eye iris pupil face
    Company & Industry Overviews

    EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24

    On July 24, EyeGate Pharmaceuticals (EYEG) announced that it has secured FDA approval for two investigational device exemption applications.

    By Margaret Patrick
  • uploads///addiction _
    Earnings Report

    How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?

    BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.

    By Daniel Collins
  • uploads///cal
    Company & Industry Overviews

    Caladrius Biosciences’ Stock Price Rose 67% on June 19

    On June 19, Caladrius Biosciences’ stock price rose 67.3% and reached $6.61 from the previous close of $3.95 on June 18.

    By Daniel Collins
  • uploads///Analysts
    Earnings Report

    Recent Developments, Recommendations for JAZZ in May

    In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application to the FDA for the label expansion of Xyrem.

    By Daniel Collins
  • uploads///Xyrem
    Earnings Report

    How Jazz Pharmaceuticals’ Products Performed in 1Q18

    In 1Q18, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $316.8 million compared to $272 million in 1Q17.

    By Daniel Collins
  • uploads///FeI
    Earnings Report

    How Did Jazz Pharmaceuticals Perform in 1Q18?

    In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17.

    By Daniel Collins
  • uploads///Shire
    Miscellaneous

    Takeda Pharmaceutical Makes 4th Successive Bid for Shire

    Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest.

    By Kenneth Smith
  • uploads///blood __
    Company & Industry Overviews

    No Bid Coming for Shire Reportedly

    Will Allergan buy Shire? – Apparently not CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier. From earlier: Shire PLC (NASDAQ: SHPG) is up 4.5% as of 11:10 A.M. on Thursday following an announcement […]

    By JP Gravitt
  • uploads///Shire
    Company & Industry Overviews

    Why Shire Stock Rose in the Week Ended March 29

    On March 29, 2018, Shire (SHPG) was trading at $149.39, which represented a 21% rise from its 52-week low of $123.73.

    By Daniel Collins
  • uploads///FD
    Company & Industry Overviews

    Alexion Pharmaceuticals in 4Q17 and Fiscal 2017

    In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Advantages of T cell immunotherapy
    Company & Industry Overviews

    A Deeper Look at Atara Biotherapeutics’ ATA129, ATA520, and ATA230

    In April 2017, Atara Biotherapeutics (ATRA) entered into an agreement with Merck (MRK) to evaluate ATA129 in combination with Merck’s Keytruda.

    By Kenneth Smith
  • uploads///Alprolix
    Company & Industry Overviews

    How Is Bioverativ’s Alprolix Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Eloctate
    Company & Industry Overviews

    How Is Bioverativ’s Eloctate Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    How Is Roche’s Hemlibra Positioned for 2018?

    Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

    By Daniel Collins
  • uploads///hemophilia
    Company & Industry Overviews

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

    By Daniel Collins
  • uploads///Xyrem
    Company & Industry Overviews

    How Is Jazz Pharmaceuticals’ Xyrem Positioned after 3Q17?

    In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $303.9 million, which reflected a rise of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Part  VNTR
    Basic Materials

    Venator to Participate in Food Ingredients Europe

    Venator, a spin-off of Huntsman (HUN), rose 0.80% and closed at $23.28 for the week ending November 24, 2017. The stock was listed on August 3, 2017.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Saw Serious Adverse Event in Fitusiran Phase 2 OLE Study

    On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had suspended all of its fitusiran studies after a serious adverse event (or SAE).

    By Margaret Patrick
  • uploads///mplx_debt
    Basic Materials

    Venator to Close 2 Facilities as Part of Business Improvement

    On September 18, 2017, Venator Materials (VNTR), a spin-off of Huntsman (HUN), announced a $90.0 million business improvement plan.

    By Peter Neil
  • uploads///Hemophilia
    Company & Industry Overviews

    A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17

    In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Alprolix Eloctate
    Company & Industry Overviews

    How Are Bioverativ’s Key Drugs Positioned after 2Q17?

    In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Erwinaze Sales May Remain Flat in 2017

    Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ’s Research Pipeline May Boost Future Revenues

    Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients

    In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).

    By Margaret Patrick
  • uploads///Global Technology IPOs
    Macroeconomic Analysis

    Why More Companies Want to Stay Private

    The equity markets across the US (SPY) (QQQ) are surging with indexes recording all-time highs in 2017.

    By Mary Sadler
  • uploads///Global Technology IPOs
    Company & Industry Overviews

    What Bob Doll Thinks about the IPO Market in 2017

    Equity market indexes across the United States are surging and recording all-time highs. The volatility index is also falling, which could be a good sign for IPO activity in 2017.

    By Mary Sadler
  • uploads///Graph
    Company & Industry Overviews

    GILD’s Positive Results from Phase 2 Trial Evaluating Selonsertib as NASH Therapy

    Gilead Sciences (GILD) is preparing to pose strong competition to other NASH players such as Allergan (AGN), Intercept Pharmaceuticals (ICPT), and Shire Pharmaceuticals (SHPG).

    By Margaret Patrick
  • uploads///krystexxa
    Company & Industry Overviews

    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug

    Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.

    By Jillian Dabney
  • uploads///lyrica
    Company & Industry Overviews

    Lyrica to Lose Patent Protection in the US in 2018

    After Pfizer lost patent protection for Lipitor, Lyrica became increasingly important to it. During its peak in 2014, Lyrica added $5.2 billion to Pfizer’s top line.

    By Jillian Dabney
  • uploads///revenue ee
    Earnings Report

    Great Disappointment in Valeant Pharmaceuticals’s 3Q16 Earnings

    Valeant Pharmaceuticals (VRX) announced its 3Q16 earnings on November 8. On a GAAP basis, Valeant reported a loss of ~$1.2 billion, which reflects a loss of $3.49 per diluted share during the period.

    By Jillian Dabney
  • uploads///salix portfolio
    Company & Industry Overviews

    Valeant’s Salix Acquisition Saga

    Valeant won the acquisition race for Salix by valuing it at $14.5 billion, inclusive of net debt. In April 2015, Valeant paid $158 per Salix share.

    By Jillian Dabney
  • uploads///hemophilia
    Earnings Report

    How Did Novo’s Biopharmaceuticals Segment Perform in 3Q16?

    Novo’s (NVO) Biopharmaceuticals segment rose 5.2 billion Danish kroner during 3Q16.

    By Jillian Dabney
  • uploads///Portfolio Breakdown of the FHJUX
    Fund Managers

    Looking at the Portfolio of the Fidelity Advisor Europe Fund

    Industrials and financials are the top two invested sectors of FHJUX, and each sector commands more than one-fifth of the portfolio.

    By David Ashworth
  • uploads///strensiq nd kanuma
    Earnings Report

    Strensiq and Kanuma: Potential Revenue Drivers for Alexion

    Once Alexion taps the numbers of Strensiq and Kanuma, its share price will most likely rise.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise

    Another franchise from Eli Lilly and Co.’s (LLY) human pharmaceuticals segment is the neuroscience franchise.

    By Mike Benson
  • uploads///NASH pipeline
    Company & Industry Overviews

    In Depth Review of Gilead Sciences’ NASH Pipeline Opportunities

    Nonalcoholic steatohepatitis (or NASH) doesn’t have any existing approved treatments on the market, but a number of companies are vying for a share of the untapped market.

    By Sarah Collins
  • uploads///BMN
    Company & Industry Overviews

    A Look at BioMarin’s Early Stage Pipeline

    BioMarin’s (BMRN) early-stage pipeline includes BMN-270, a gene therapy program for hemophilia A and vosoritide, which is indicated for achondroplasia.

    By Jillian Dabney
  • uploads///sovaldi patients
    Company & Industry Overviews

    How Gilead Dominates the HCV Space

    In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.

    By Jillian Dabney
  • uploads///horizon as orphan drug company
    Company & Industry Overviews

    Buy Allows Horizon to Further Expand into Orphan Drug Space

    Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.

    By Jillian Dabney
  • uploads///deal benefits
    Company & Industry Overviews

    News of Acquisition Caused Horizon Pharma Stock to Rise

    The market was pleased with the merger deal between Horizon Pharma (HZNP) and Raptor Pharmaceuticals. HZNP shares rose to $18.89 on September 12.

    By Jillian Dabney
  • uploads///deal details
    Company & Industry Overviews

    How the Numbers Add Up for the Horizon Pharma–Raptor Deal

    According to the September 12, 2016, agreement between Horizon Pharma (HZNP) and Raptor Pharmaceuticals, HZNP will acquire Raptor common stock at $9 per share.

    By Jillian Dabney
  • uploads///vaccine
    Company & Industry Overviews

    Sanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price

    Sanofi’s Vaccine segment generated 1.4 billion euros, or about $1.6 billion, during the first half of 2016.

    By Jillian Dabney
  • uploads///hemophilia revenue
    Company & Industry Overviews

    Why Are Revenues from Pfizer’s Rare Disease Portfolio Falling?

    BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million.

    By Jillian Dabney
  • uploads///lyrica
    Company & Industry Overviews

    How Pfizer’s Internal Medicine Core Drugs Are Performing

    The major contributors in Pfizer’s (PFE) Internal Medicine business include Lyrica and Viagra. Lyrica’s Innovative Health (or IH) contribution to the Internal Medicine portfolio stood at 48%.

    By Jillian Dabney
  • uploads///acquisition
    Company & Industry Overviews

    What’s behind Mallinckrodt’s Stratatech Acquisition?

    Stratatech is a regenerative medicine company with a focus on the development of proprietary skin substitute products.

    By Jillian Dabney
  • uploads///Roche growth
    Company & Industry Overviews

    Why Roche Might Be Interested in BioMarin

    With increased M&A activity in the pharmaceuticals and biotechnology space, it wouldn’t be surprising if Roche Holding (RHHBY) acquired BioMarin (BMRN).

    By Jillian Dabney
  • uploads///biopharmaceuticals revenue mix
    Company & Industry Overviews

    What Are the Prospects for Novo’s Biopharmaceuticals Segment?

    Novo’s (NVO) biopharmaceuticals segment sales grew by 6% on a reported basis to amount to 11.8 billion Danish kroner during 1H16.

    By Jillian Dabney
  • uploads///PE and share price
    Company & Industry Overviews

    Pfizer’s Medivation Acquisition: What You Need to Know

    On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.

    By Jillian Dabney
  • uploads///pipeline
    Earnings Report

    An Update on Shire’s Upcoming Milestones

    Shire anticipates receiving European Union approval for Natpara for the indication of hyperparathyroidism in 4Q16.

    By Jillian Dabney
  • uploads///revenue ee
    Earnings Report

    What’s behind Shire’s 2Q16 Earnings Surprise?

    On August 2, 2016, Shire (SHPG) surprised analysts by reporting sales of $2.4 billion for 2Q16. Analysts expected $2.3 billion.

    By Jillian Dabney
  • uploads///operational paramets
    Earnings Report

    Can Valeant’s Margins for 2Q16 Meet Expectations?

    During 4Q15 and 1Q16, Valeant Pharmaceuticals’ (VRX) net margin turned negative. That followed its struggling high-margin dermatology products and the foreign exchange impact.

    By Jillian Dabney
  • uploads///RD
    Earnings Report

    How Critical Is Valeant’s Pipeline to Its Success?

    Valeant’s (VRX) prospects depend on the success of its pipeline candidates since they can drive the pressured top line of the much-troubled company.

    By Jillian Dabney
  • uploads///fin projections
    Earnings Report

    What to Expect from Valeant’s Upcoming Q216 Earnings

    Wall Street analysts anticipate that Valeant will record $2.47 billion and $2.54 billion total revenue for 2Q16 and 3Q16, respectively.

    By Jillian Dabney
  • uploads///ANR
    Earnings Report

    BioMarin: Why So Many ‘Buy’ Recommendations?

    BioMarin (BMRN) is expected to report 2Q16 earnings on August 4, 2016. “Buy” ratings have increased to 94.7% from 90% on June 29, 2016.

    By Jillian Dabney
  • uploads///soliris opportunity
    Earnings Report

    How Significant Is Alexion’s Opportunity with Soliris?

    Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.

    By Jillian Dabney
  • uploads///LSD portfolio
    Earnings Report

    How Will Shire’s LSD Portfolio Perform in 2016?

    Shire’s (SHPG) LSD (or lysosomal storage disorders) portfolio consists of Elaprase, Replagal, and Vpriv.

    By Jillian Dabney
  • uploads///human geentics therapies
    Earnings Report

    What to Expect from Shire’s Genetic Disease Franchise

    Wall Street analysts expect Elaprase to earn $145.6 million in 2Q16 and $140.5 million in 3Q16.

    By Jillian Dabney
  • uploads///ADHD Franchise
    Earnings Report

    How Will Shire’s ADHD Franchise Perform in 2Q16?

    Shire’s (SHPG) ADHD franchise includes Vyvanse, Adderall XR, and Intuniv.

    By Jillian Dabney
  • uploads///ANR
    Earnings Report

    How Analysts Think Investors Should Play Vertex Pharmaceuticals

    Vertex Pharmaceuticals (VRTX) will report its 2Q16 earnings on July 27, 2016. Based in Boston, VRTX is a global biotechnology company that primarily focuses on cystic fibrosis drugs.

    By Jillian Dabney
  • uploads///Strensiq
    Earnings Report

    How Alexion Plans to Fuel Strensiq Sales

    With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Inside Lilly’s 2Q16 Estimates for Its Neuroscience Franchise

    Another franchise in Eli Lilly’s Human Pharmaceuticals segment is the neuroscience franchise, which contributes ~13% of Lilly’s total revenues.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Biogen’s Hemophilia Drugs Could See Strong Revenue Growth

    Biogen (BIIB) discussed its plans to spin off its haemophilia franchise into an independent, publicly traded company.

    By Margaret Patrick
  • uploads///dupilumab
    Earnings Report

    Regeneron’s Dupilumab: How Much Potential Does It Hold?

    Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.

    By Jillian Dabney
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///pegvaliase for PKU
    Company & Industry Overviews

    Understanding the Valuation Catalysts for BioMarin in 4Q16

    BioMarin plans to file a Biologics License Application with the FDA for Pegvaliase, which is indicated to treat phenylketonuria, by the end of fiscal 2016.

    By Jillian Dabney
  • uploads///pipeline
    Company & Industry Overviews

    Understanding Alexion’s Robust Pipeline

    Alexion is expanding the label for its key drug Soliris. Along with Soliris, Alexion’s has several other key molecules in the advanced development stage.

    By Jillian Dabney
  • uploads///Eculizumab
    Company & Industry Overviews

    What Are the Additional Labels for Alexion’s Soliris?

    Soliris is Alexion’s leading drug. It was approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in 2007 and 2011.

    By Jillian Dabney
  • uploads///business segments
    Company & Industry Overviews

    Why Are Novo Nordisk’s Two Segments Growing?

    Novo Nordisk (NVO) operates in two major segments: diabetes and obesity care and biopharmaceuticals. Diabetes care has been Novo’s major business area.

    By Jillian Dabney
  • uploads///shp
    Company & Industry Overviews

    How Does Shire’s Late-Stage Pipeline Look?

    SHP643, a phase three candidate, might present significant growth potential for Shire (SHPG) in the hereditary angioedema (or HAE) space.

    By Jillian Dabney
  • uploads///RD
    Company & Industry Overviews

    How Shire’s Robust Pipeline Could Drive Its Valuation

    With the completion of the Baxalta acquisition, Shire (SHPG) has 50 inline and pipeline products and programs.

    By Jillian Dabney
  • uploads///flagship products
    Company & Industry Overviews

    What Are Shire’s Flagship Products?

    Shire’s (SHPG) portfolio spans across diversified areas such as neuroscience, hematology, immunology, genetic diseases, internal medicine, and ophthalmics.

    By Jillian Dabney
  • uploads/// guidance
    Company & Industry Overviews

    What Is Shire’s Outlook for 2016?

    Shire (SHPG) expects to generate 13%–17% higher product sales on a constant exchange rate (or CER) basis in fiscal 2016.

    By Jillian Dabney
  • uploads///PE
    Company & Industry Overviews

    What’s behind Shire’s Attractive Valuation?

    Shire has a diversified portfolio and a robust rare disease pipeline. Following the Baxalta acquisition, its top line is expected to grow exponentially.

    By Jillian Dabney
  • uploads///annual revenue
    Company & Industry Overviews

    Valeant: The Rise and Fall of a Giant Specialty Pharmaceutical

    Much of Valeant’s growth was coming from price increases rather than volume gains, and that wasn’t sustainable. The company’s steep price increases came under regulator scrutiny.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%

    As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Shire’s Shareholders Approve Baxalta Merger: What’s Next?

    Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Grifols Maintains Its Dividend Payout at 40%

    Grifols (GRFS) outperformed other international securities within IBB with a return of 8.5% for the week ending May 27 as it announced a dividend payment.

    By Peter Neil
  • uploads///soliris
    Earnings Report

    Inside Soliris’s Continued Growth Momentum

    During the first quarter of 2016, Alexion Pharmaceuticals (ALXN) earned $664.7 million from the sale of its flagship drug, Soliris.

    By Jillian Dabney
  • uploads///Share price
    Earnings Report

    Understanding Alexion’s Share Price Performance since Its Previous Earnings

    Alexion reported a revenue decline of 1.5% and an earnings decline of 2.2% in 1Q16, which surprised investors and led to a 6% fall in its share price.

    By Jillian Dabney
  • uploads///Share price
    Earnings Report

    How Has Novo’s Share Price Performed since Its Last Earnings?

    Novo Nordisk announced its earnings for fiscal 2015 on February 3, 2016. Disappointment in its earnings per share saw its share price fall 6% on the day.

    By Jillian Dabney
  • uploads///CF opportunity
    Earnings Report

    A Look at Vertex’s Cystic Fibrosis Patient Opportunity

    There are ~27,000 eligible patients for Vertex Pharmaceuticals’ Kalydeco and Orkambi. However, Vertex is only currently treating one-third of patients.

    By Jillian Dabney
  • uploads///CF leadership
    Earnings Report

    How Much Potential Does Vertex’s CF Pipeline Hold?

    To maintain leadership in the cystic fibrosis space, Vertex Pharmaceuticals has to come up with superior molecules that offer enhanced clinical benefits.

    By Jillian Dabney
  • Company & Industry Overviews

    Timely Energy Exposure Helped FHJUX in 1Q16

    The Fidelity Advisor Europe Fund – Class A (FHJUX) fell 1.8% in 1Q16. But it still emerged as an above-average performer among the 12 funds in this review.

    By David Ashworth
  • uploads///Portfolio Breakdown of the FHJUX
    Fund Managers

    Sector Composition Changes in FHJUX until 1Q16

    FHJUX’s assets were spread across 73 holdings as of March 2016, which is six less than a quarter ago. It was managing assets worth $1.3 billion as of the end of March.

    By David Ashworth
  • uploads///Share price after shire baxalta deal
    Company & Industry Overviews

    The Shire-Baxalta Merger: A Look at the Details

    Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.

    By Jillian Dabney
  • uploads///VOD
    Company & Industry Overviews

    Defitelio: Volume and Pricing Challenges

    Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).

    By Jillian Dabney
  • uploads///xyrem
    Company & Industry Overviews

    Xyrem: Jazz Pharmaceuticals’ Key Product

    Xyrem is the only FDA-approved drug for both cataplexy and EDS (excessive daytime sleepiness) with narcolepsy.

    By Jillian Dabney
  • uploads///lialda
    Company & Industry Overviews

    Shire Won Patent Infringement Case for Lialda

    In fiscal 2015, Lialda added $684.4 million to Shire’s (SHPG) top line, reflecting an 8% annual increase in sales. This was supported by a 10% rise in prescription volume.

    By Jillian Dabney
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.